Volume 2.24 | Jul 8

Prostate Cell News 2.24, July 8, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Deep Sequencing Reveals Distinct Patterns of DNA Methylation in Prostate Cancer
Researchers mapped the global DNA methylation patterns in select prostate tissues and cell lines using MethylPlex–next-generation sequencing. [Genome Res]

Inovio Pharmaceuticals’ Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
Inovio Pharmaceuticals, Inc. announced that its therapeutic DNA vaccine for prostate cancer showed remarkable immune responses in monkeys, following similarly strong, antigen-specific and sustainable T cell levels in previously reported data from earlier animal studies. [Press release from Inovio Pharmaceuticals, Inc. discussing research presented at the BIO International Convention]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


A Viral Strategy to Ambush Tumors
A new combinatorial approach harnesses the power of immuno- and virotherapy in a vesicular stomatitis virus vector carrying a complimentary DNA library that expresses normal human prostate antigens, thus providing proof of principle that this vaccine can induce prostate tumor rejection in mice. [Nat Med]

Targeting the Regulation of Androgen Receptor Signaling by the Heat Shock Protein 90 Cochaperone FKBP52 in Prostate Cancer Cells
Researchers used a modified receptor-mediated reporter assay in yeast to screen a diversified natural compound library for inhibitors of FKBP52-enhanced androgen receptor function. [Proc Natl Acad Sci]

Clusterin Inhibition Using OGX-011 Synergistically Enhances Hsp90 Inhibitor Activity by Suppressing the Heat Shock Response in Castrate Resistant Prostate Cancer
Researchers hypothesized that preventing clusterin induction in heat shock response would enhance heat shock protein 90 (Hsp90) inhibitor-induced castration-resistant prostate cancer cell death in vitro and in vivo. [Cancer Res]

Valproic Acid Synergistically Enhances the Cytotoxicity of Gossypol in DU145 Prostate Cancer Cells: An Isobaric Tag for Relative and Absolute Quantitation-Based Quantitative Proteomic Analysis
In this study, researchers found that valproic acid, a histone deacetylase inhibitor, counteracted the suppressive effect of gossypol (GOS) on histone H3 acetylation and enhanced the cytotoxicity of GOS to DU145 prostate cancer cells. [J Proteomics]

Inecalcitol, an Analog of 1α,25(OH)2D3, Induces Growth Arrest of Androgen-Dependent Prostate Cancer Cells
Researchers evaluated the activity of inecalcitol in a human prostate cancer model system. [Int J Cancer]

Suppression of STAT3 and Hypoxia-Inducible Factor 1 Alpha Mediates Anti-Angiogenic Activity of Betulinic Acid in Hypoxic PC-3 Prostate Cancer Cells
In the present study, researchers examined that betulinic acid, a triterpene from the bark of white birch, had the inhibitory effects on hypoxia-mediated activation of signal transducer and activator of transcription 3 (STAT3) in androgen independent human prostate cancer PC-3 cells. [PLoS One]

Mda-7/IL-24 Differentially Regulates Soluble and Nuclear Clusterin in Prostate Cancer
Researchers identify clusterin (CLU) as a melanoma differentiation-associated gene-7/interleukin-24 (MDA-7/IL-24) interacting protein in DU-145 cells and investigate the role of MDA-7/IL-24 in regulating CLU expression and mediating the antitumor properties of mda-7/IL-24 in prostate cancer. [J Cell Physiol]


Clinically Significant Gleason Sum Upgrade: External Validation and Head-to-Head Comparison of the Existing Nomograms
In this study, the authors evaluated and compared the ability of 4 nomograms to predict gleason sum (GS) upgrades for patients with biopsy GS ≤6 prostate cancer who underwent radical prostatectomy at their center. [Cancer]

Poorer Outcome in Polynesian Patients with Prostate Cancer Treated with Definitive Conformational Radiation Therapy
The purpose of this study is to compare freedom from biochemical failure of French Polynesian and Native European prostate cancer patients after definitive conformal radiotherapy. [Radiother Oncol]

Early Continence in Patients with Localized Prostate Cancer. A Comparison Between Open Retropubic (RRPE) and Endoscopic Extraperitoneal Radical Prostatectomy (EERPE)
Researchers examined and compared continence rates in prostate cancer patients who had undergone either open RRPE or EERPE. [Urol Oncol]

Tumor Volume, Surgical Margin, and the Risk of Biochemical Recurrence in Men with Organ-Confined Prostate Cancer
Researchers proposed to investigate predictors of biochemical recurrence in pT2 prostate cancer by identifying the interrelationship between the tumor volume and surgical margin status, and their impact on recurrence. [Urol Oncol]

Predictive Value of Digital Rectal Examination for Prostate Cancer Detection Is Modified by Obesity
Data from 2794 men undergoing initial prostate biopsy at three centers were analyzed to assess prostate cancer risk attributed to abnormal digital rectal examination across body mass index categories. [Prostate Cancer Prostatic Dis]


Canary Foundation Researchers Receive Department of Defense Grants for Over $2 million to Fund Prostate Cancer Research
Canary Foundation’s Canary Prostate Team has been awarded two Department of Defense grants issued by the United States Army Medical Research Acquisition Activity. Totaling $2.25 million, these grants will help fund prostate cancer research. [Canary Foundation Press Release]

Precision Biopsy Secures New Funding Led by Allied Minds, Inc.
Precision Biopsy formally closed a $2.5 million round of funding to kickoff the commercialization phase of a novel prostate cancer detection technology developed at the University of Colorado Anschutz Medical Campus. [Allied Minds, Inc. Press Release]

Inovio Expands DNA Vaccine Intellectual Property License with the University of Pennsylvania
Inovio Pharmaceuticals, Inc. announced that it has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against prostate cancer, cytomegalovirus, malaria, hepatitis B, respiratory syncytial virus, and methicillin-resistant staphylococcus aureus. [Inovio Pharmaceuticals, Inc. Press Release]

Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Dendreon Corporation announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. [Dendreon Corporation Press Release]

Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
Amgen announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. [Amgen, Inc. Press Release]

Phase III Trial of ZALTRAP™ (aflibercept) in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Regeneron Pharmaceuticals, Inc. announced that the Phase III VENICE clinical trial evaluating the investigational agent ZALTRAP™ (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns. [Regeneron Pharmaceuticals, Inc. Press Release]

Medicare to Cover Dendreon’s Prostate Drug
The U.S. Centers for Medicare and Medicaid ruled that there is adequate evidence to pay for Provenge, saying it is “reasonable and necessary” for treating men with advanced prostate cancer whose disease has spread. [Medicare, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 2011 World Stem Cell Summit  
October 3-5, 2011 
Pasadena, United States 

NEW World Stem Cells & Regenerative Medicine Congress Asia 2011 
October 11-13, 2011 
Singapore, Singapore 

NEW Days of Molecular Medicine 2011 – Re-Engineering Regenerative Medicine 
November 10-12, 2011 
Hong Kong

Visit our events page to see a complete list of events in the prostate cell community.


Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Post-doctoral Position – Molecular Biology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us